Financial
Latest full-year results from official filings.
FY2025 revenue €3.48bn (+3.3%); operating margin 6.7%; net income €140.4m.
Balance sheet figures not captured from release.
- Official results release · Dräger · 31 Dec 2025
Dräger: risk summary
Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Adverse media
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Mar 2026: Dräger said it is cutting a low three-digit number of safety-technology jobs at Lübeck by 2028, moving some production to the Czech Republic, and has closed several German sales sites; it said cuts will come through attrition.
- Dräger kürzt am Standort Deutschland · Börsen-Zeitung · 6 Mar 2026
Cyber & information governance
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator action involving Dräger found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Regulatory & clinical safety
Recalls, safety notices, regulator action and clinical safety concerns.
Jan 2026: Dräger recalled certain Vapor 2000 and Vapor 3000 anaesthetic vaporisers after metal residue from a supplier's soldering was found inside, posing potential airway and lung risks; no injuries were reported in the notice.
- Anesthetic Vaporizer Recall: Draeger Removes Certain Vapor 2000 and Vapor 3000 Vaporizers · American Society of Anesthesiologists (FDA alert) · 16 Jan 2026
Contract performance
Contract delivery, go-lives, terminations and disputes.
No notable go-lives, troubled implementations, terminations or customer disputes involving Dräger found in HSH's search of the last 24 months.